retatrutide clinical trial phase 3: TRIUMPH Program Results 2026 Retatrutide Phase 3 Results: Trials,

Per the Ridha 2024 Aesthetic Surgery Journal paper (PMID 38874170), the temporal fat pad is among the most affected compartments

By product, the Ozempic segment dominated the market in 2024

If chest pain persists beyond 48 hours, worsens despite conservative care, or develops new concerning features, schedule an urgent evaluation with your primary care physician or seek emergency department assessment

Key safety observations from available trial data include: Elevated resting heart rate in a dose-dependent manner Gastrointestinal adverse effects (nausea, vomiting, diarrhoea) as the most common side effects, consistent with the GLP-1 receptor agonist class [1] [3] No clinically significant QT interval prolongation was reported in available data, though the extent of formal thorough QT assessment has not been fully detailed in published sources